These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38745749)

  • 1. Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
    Tran TQ; Grein J; Selman M; Annamalai L; Yearley JH; Blumenschein WM; Sadekova S; Chackerian AA; Phan U; Wong JC
    Mol Ther Oncol; 2024 Jun; 32(2):200807. PubMed ID: 38745749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.
    Parra-Guillen ZP; Freshwater T; Cao Y; Mayawala K; Zalba S; Garrido MJ; de Alwis D; Troconiz IF
    Front Pharmacol; 2021; 12():705443. PubMed ID: 34366859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
    Curti BD; Richards J; Hyngstrom JR; Daniels GA; Faries M; Feun L; Margolin KA; Hallmeyer S; Grose M; Zhang Y; Li A; Andtbacka RHI
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
    Rudin CM; Pandha HS; Zibelman M; Akerley WL; Harrington KJ; Day D; Hill AG; O'Day SJ; Clay TD; Wright GM; Jennens RR; Gerber DE; Rosenberg JE; Ralph C; Campbell DC; Curti BD; Merchan JR; Ren Y; Schmidt EV; Guttman L; Gupta S
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36669791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy.
    Sakunchotpanit G; Patil MK; Venkatesh K; Rohan TZ; Cheng D; Nambudiri VE
    Exp Dermatol; 2024 Sep; 33(9):e15169. PubMed ID: 39207089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
    Silk AW; O'Day SJ; Kaufman HL; Bryan J; Norrell JT; Imbergamo C; Portal D; Zambrano-Acosta E; Palmeri M; Fein S; Wu C; Guerreiro L; Medina D; Bommareddy PK; Zloza A; Fox BA; Ballesteros-Merino C; Ren Y; Shafren D; Grose M; Vieth JA; Mehnert JM
    Cancer Immunol Immunother; 2023 Jun; 72(6):1405-1415. PubMed ID: 36445410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    Andtbacka RHI; Curti B; Daniels GA; Hallmeyer S; Whitman ED; Lutzky J; Spitler LE; Zhou K; Bommareddy PK; Grose M; Wang M; Wu C; Kaufman HL
    J Clin Oncol; 2021 Dec; 39(34):3829-3838. PubMed ID: 34464163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.
    Deng JZ; Rustandi RR; Swartz A; Shieh Y; Baker JB; Vlasak J; Wang S; Loughney JW
    Mol Ther Oncolytics; 2022 Mar; 24():139-147. PubMed ID: 35024440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification.
    Deng JZ; Rustandi RR; Barbacci D; Swartz AR; Gulasarian A; Loughney JW
    Hum Gene Ther; 2022 Jul; 33(13-14):765-775. PubMed ID: 35387488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling.
    Parra-Guillen ZP; Sancho-Araiz A; Mayawala K; Zalba S; Garrido MJ; de Alwis D; Troconiz IF; Freshwater T
    Clin Pharmacol Ther; 2023 Sep; 114(3):623-632. PubMed ID: 37170933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
    Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
    J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
    Relph K; Annels N; Smith C; Kostalas M; Pandha H
    Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
    Skelding KA; Barry RD; Shafren DR
    Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.
    Shafren DR; Au GG; Nguyen T; Newcombe NG; Haley ES; Beagley L; Johansson ES; Hersey P; Barry RD
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):53-60. PubMed ID: 14734451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
    Annels NE; Mansfield D; Arif M; Ballesteros-Merino C; Simpson GR; Denyer M; Sandhu SS; Melcher AA; Harrington KJ; Davies B; Au G; Grose M; Bagwan I; Fox B; Vile R; Mostafid H; Shafren D; Pandha HS
    Clin Cancer Res; 2019 Oct; 25(19):5818-5831. PubMed ID: 31273010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
    Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
    Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
    Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
    Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western.
    Gillespie PF; Rustandi RR; Swartz AR; Shang L; Raffaele J; Prout A; Cunningham N; Dawod M; Deng JZ; Wang S; Olson J; Shieh Y; Loughney JW
    Hum Gene Ther; 2023 Jan; 34(1-2):68-77. PubMed ID: 36503264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
    Annels NE; Arif M; Simpson GR; Denyer M; Moller-Levet C; Mansfield D; Butler R; Shafren D; Au G; Knowles M; Harrington K; Vile R; Melcher A; Pandha H
    Mol Ther Oncolytics; 2018 Jun; 9():1-12. PubMed ID: 29989024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.